Mergers & Acquisitions ·
VYNE Therapeutics Inc. held a special meeting on July 16, 2026, where stockholders approved several key proposals…
VYNEYarrow Bioscience, Inc.
VYNE Therapeutics Inc. held a special meeting on July 16, 2026, where stockholders approved several key proposals related to its merger with Yarrow Bioscience, Inc. Approved measures include the issuance of VYNE common stock to Yarrow stockholders, an amendment to the charter to increase authorized shares from 150,000,000 to 300,000,000, and a reverse stock split with a ratio between 1-for-10 and 1-for-70. Additionally, stockholders approved the Yarrow Bioscience 2026 Stock Incentive Plan, the 2026 Employee Stock Purchase Plan, the election of Sharon Barbari to the board, the ratification of Baker Tilly US, LLP as independent auditors, and advisory votes on executive compensation. VYNE Therapeutics Inc. is a biotechnology company.